Фундаментальные и клинические аспекты заболеваний щитовидной железы и новые подходы для их лечения (обзор литературы)

Автор: Фокина Е.А., Шпаков А.О.

Журнал: Сибирский журнал клинической и экспериментальной медицины @cardiotomsk

Статья в выпуске: 3 т.37, 2022 года.

Бесплатный доступ

Распространенность заболеваний щитовидной железы (ЩЖ), в том числе аутоиммунного гипертиреоза (болезни Грейвса), аутоиммунного тиреоидита, различных форм тиреоидного рака, с каждым годом возрастает, в то время как эффективность их лечения по-прежнему остается низкой и ограничивается в основном заместительной терапией тиреоидными гормонами и хирургическими и радиоизотопными методами. В настоящем обзоре представлено современное состояние проблемы фармакологической коррекции заболеваний ЩЖ, рассмотрены новые подходы, направленные на регуляцию функциональной активности компонентов системы синтеза тиреоидных гормонов в фолликулярных клетках ЩЖ, включая его начальный, сенсорный, компонент - рецептор тиреотропного гормона. Среди препаратов, которые разрабатываются в настоящее время, необходимо выделить аллостерические регуляторы рецептора тиреотропного гормона, специфичные к нему антитела, а также селективные агонисты β-изоформы рецепторов тиреоидных гормонов.

Еще

Щитовидная железа, рецептор тиреотропного гормона, тиреоидные гормоны, фармакотерапия, антитиреоидные препараты

Короткий адрес: https://sciup.org/149141439

IDR: 149141439 | DOI: 10.29001/2073-8552-2022-37-3-90-97

Список литературы Фундаментальные и клинические аспекты заболеваний щитовидной железы и новые подходы для их лечения (обзор литературы)

GBD 2017 Mortality Collaborators. Global, regional, and national age-sex-specific mortality and life expectancy, 1950-2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1684-1735. DOI: 10.1016/S0140-6736(18)31891-9.
Vanderpump M.P.J. Epidemiology of thyroid disorders. In: Luster M., Duntas L., Wartofsky L. (eds.). The thyroid and its diseases. Springer International Publishing AG; 2019:75-85. DOI: 10.1007/978-3-319-72102-6_6.
Vanderpump M.P. The epidemiology of thyroid disease. Br. Med. Bull. 2011;99:39-51. DOI: 10.1093/bmb/ldr030.
Chaker L., Razvi S., Bensenor I.M., Azizi F., Pearce E.N., Peeters R.P. Hypothyroidism Nat. Rev. Dis. Primers. 2022;8(1):30. DOI: 10.1038/ s41572-022-00357-7.
Burch H.B., Cooper D.S. Management of Graves Disease: A Review. JAMA. 2015;314(23):2544-2554. DOI: 10.1001/jama.2015.16535.
Wemeau J.L., Klein M., Sadoul J.L., Briet C., Velayoudom-Cephise F.L. Graves' disease: Introduction, epidemiology, endogenous and environmental pathogenic factors. Ann. Endocrinol. (Paris). 2018;79(6):599-607. DOI: 10.1016/j.ando.2018.09.002.
Brix T.H., Kyvik K.O., Christensen K., Hegedüs L. Evidence for a major role of heredity in Graves' disease: a population-based study of two Danish twin cohorts. J. Clin. Endocrinol. Metab. 2001;86(2):930-934. DOI: 10.1210/jcem.86.2.7242.
Antonelli A., Ferrari S.M., Ragusa F., Elia G., Paparo S.R., Ruffil-li I. et al. Graves' disease: Epidemiology, genetic and environmental risk factors and viruses. Best Pract. Res. Clin. Endocrinol. Metab. 2020;34(1):101387. DOI: 10.1016/j.beem.2020.101387.
Kisiel B., Bednarczuk T., Kostrzewa G., Kosinska J., Miskiewicz P., Ptazinska M.T. et al. Polymorphism of the oestrogen receptor beta gene (ESR2) is associated with susceptibility to Graves' disease. Clin. Endocrinol. (Oxf.). 2008;68(3):429-434. DOI: 10.1111/j.1365-2265.2007.03060.x.
Cury S.S., Oliveira M., Sibio M.T., Clara S., Luvizotto Rd. A., Conde S. et al. Gene expression of estrogen receptor-alpha in orbital fibroblasts in Graves' ophthalmopathy. Arch. Endocrinol. Metab. 2015;59(3):273-276. DOI: 10.1590/2359-3997000000050.
Brix T.H., Knudsen G.P., Kristiansen M., Kyvik K.O., Orstavik K.H., Hegedüs L. High frequency of skewed X-chromosome inactivation in females with autoimmune thyroid disease: A possible explanation for the female predisposition to thyroid autoimmunity. J. Clin. Endocrinol. Metab. 2005;90(11):5949-5953. DOI: 10.1210/jc.2005-1366.
Simmonds M.J., Kavvoura F.K., Brand O.J., Newby P.R., Jackson L.E., Hargreaves C.E. et al. Skewed X chromosome inactivation and female preponderance in autoimmune thyroid disease: An association study and meta-analysis. J. Clin. Endocrinol. Metab. 2014;99(1):E127-E131. DOI: 10.1210/jc.2013-2667.
Ferrari S.M., Fallahi P., Antonelli A., Benvenga S. Environmental issues in thyroid diseases. Front. Endocrinol. (Lausanne). 2017;8:50. DOI: 10.3389/fendo.2017.00050.
Bürgi H. Iodine excess. Best Pract. Res. Clin. Endocrinol. Metab. 2010;24(1):107-115. DOI: 10.1016/j.beem.2009.08.010.
Kahaly G.J., Bartalena L., Hegedüs L. The American Thyroid Association/American Association of Clinical Endocrinologists guidelines for hy-perthyroidism and other causes of thyrotoxicosis: A European perspective. Thyroid. 2011;21(6):585-591. DOI: 10.1089/thy.2011.2106.ed3.
Kahaly G.J., Bartalena L., Hegedüs L., Leenhardt L., Poppe K., Pearce S.H. 2018 European Thyroid Association Guideline for the Management of Graves' Hyperthyroidism. Eur. Thyroid J. 2018;7(4):167-186. DOI: 10.1159/000490384.
Burch H.B., Cooper D.S. Antithyroid drug therapy: 70 years later. Eur. J. Endocrinol. 2018;179(5):R261-R274. DOI: 10.1530/EJE-18-0678.
Bartalena L., Piantanida E., Gallo D., Ippolito S., Tanda M.L. Management of Graves' hyperthyroidism: Present and future. Expert Rev. Endocrinol. Metab. 2022;17(2):153-166. DOI: 10.1080/17446651.2022.2052044.
Vos X.G., Endert E., Zwinderman A.H., Tijssen J.G., Wiersinga W.M. Predicting the risk of recurrence before the start of antithyroid drug therapy in patients with graves' hyperthyroidism. J. Clin. Endocrinol. Metab. 2016;101(4):1381-1389. DOI: 10.1210/jc.2015-3644.
Azizi F., Ataie L., Hedayati M., Mehrabi Y., Sheikholeslami F. Effect of long-term continuous methimazole treatment of hyperthyroidism: comparison with radioiodine. Eur. J. Endocrinol. 2005;152(5):695-701. DOI: 10.1530/eje.1.01904.
Aung E.T., Zammitt N.N., Dover A.R., Strachan M.W.J., Seckl J.R., Gibb F.W. Predicting outcomes and complications following radioiodine therapy in Graves' thyrotoxicosis. Clin. Endocrinol. (Oxf.). 2019;90(1):192-199. DOI: 10.1111/cen.13873.
Bonnema S.J., Hegedus L. Radioiodine therapy in benign thyroid diseases: Effects, side effects, and factors affecting therapeutic outcome. En-docr. Rev. 2012;33(6):920-980. DOI: 10.1210/er.2012-1030.
Walter M.A., Briel M., Christ-Crain M., Bonnema S.J., Connell J., Cooper D.S. et al. Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials. BMJ. 2007;334(7592):514. DOI: 10.1136/bmj.39114.670150.BE.
Metso S., Jaatinen P., Huhtala H., Auvinen A., Oksala H., Salmi J. Increased cardiovascular and cancer mortality after radioiodine treatment for. J. Clin. Endocrinol. Metab. 2007;92(6):2190-2196. DOI: 10.1210/ jc.2006-2321.
Bartalena L., Piantanida E., Tanda M.L. Can a patient-tailored treatment approach for Graves' disease reduce mortality? Lancet Diabetes Endocrinol. 2019;7(4):245-246. DOI: 10.1016/S2213-8587(19)30057-9.
Pearce S.H.S., Dayan C., Wraith D.C., Barrell K., Olive N., Jansson L. et al. Antigen-pecific Immunotherapy with Thyrotropin Receptor Peptides in Graves' Hyperthyroidism: A Phase I Study. Thyroid. 2019;29(7):1003-1011. DOI: 10.1089/thy.2019.0036.
Furmaniak J., Sanders J., Sanders P., Li Y., Rees Smith B. TSH receptor specific monoclonal autoantibody K1-70™ targeting of the TSH receptor in subjects with Graves> disease and Graves> orbitopathy - Results from a phase I clinical trial. Clin. Endocrinol. (Oxf.). 2022;96(6):878-887. DOI: 10.1111/cen.14681.
Krause G., Eckstein A., Schulein R. Modulating TSH receptor signaling for therapeutic benefit. Eur. Thyroid. J. 2020;9(1):66-77. DOI: 10.1159/000511871.
Kang S.Y., Seo J., Kang H.R. Desensitization for the prevention of drug hypersensitivity reactions. Korean J. Intern. Med. 2022;37(2):261-270. DOI: 10.3904/kjim.2021.438.
Cox L. Grand challenges in allergen immunotherapy. Front. Allergy. 2021;2:710345. DOI: 10.3389/falgy.2021.710345.
Pavanello F., Zucca E., Ghielmini M. Rituximab: 13 open questions after 20-years of clinical use. Cancer Treat. Rev. 2017;53:38-46. DOI: 10.1016/j.ctrv.2016.11.015.
Lane L.C., Cheetham T.D., Perros P., Pearce S.H.S. New therapeutic horizons for Graves' hyperthyroidism. Endocr. Rev. 2020;41(6):873-884. DOI: 10.1210/endrev/bnaa022.
El Fassi D., Nielsen C.H., Junker P., Hasselbalch H.C., Hegedus L. Systemic adverse events following rituximab therapy in patients with Graves' disease. J. Endocrinol. Invest. 2011;34(7):e163-e167. DOI: 10.3275/7411.
Shpakov A.O. Endogenous and synthetic regulators of the peripheral components of the hypothalamo-hypophyseal-gonadal and - thyroid axes. Neurosci. Behav. Physi. 2021;51:332-345. DOI: 10.1007/s11055-021-01076-4.
Latif R., Realubit R.B., Karan C., Mezei M., Davies T.F. TSH receptor signaling abrogation by a novel small molecule. Front. Endocrinol. (Lausanne). 2016;7:130. DOI: 10.3389/fendo.2016.00130.
Marcinkowski P., Kreuchwig A., Mendieta S., Hoyer I., Witte F., Furkert J. et al. Thyrotropin receptor: Allosteric modulators illuminate intramolecular signaling mechanisms at the interface of ecto- and transmembrane domain. Mol. Pharmacol. 2019;96(4):452-462. DOI: 10.1124/ mol.119.116947.
Derkach K.V., Bakhtyukov A.A., Sorokoumov V.N., Shpakov A.O. New Thieno-[2,3-d]pyrimidine-based functional antagonist for the receptor of thyroid stimulating hormone. Dokl. Biochem. Biophys. 2020;491(1):77-80. DOI: 10.1134/S1607672920020064.
Bakhtyukov A., Derkach K., Sorokoumov V., Fokina E., Shpakov A.O. The development of new low-molecular-weight allosteric antagonists of thyroid-stimulating hormone receptor and their effect on the basal and thyroliberin-stimulated production of thyroid hormones. FEBS Open Bio. 2021;11(1):87-88. DOI: 10.1002/2211-5463.13205.
Hollowell J.G., Staehling N.W., Flanders W.D., Hannon W.H., Gunter E.W., Spencer C.A. et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J. Clin. Endocrinol. Metab. 2002;87(2):489-499. DOI: 10.1210/jcem.87.2.8182.
Stoppa-Vaucher S., Van Vliet G., Deladoey J. Variation by ethnicity in the prevalence of congenital hypothyroidism due to thyroid dysgenesis. Thyroid. 2011;21(1):13-18. DOI: 10.1089/thy.2010.0205.
Teumer A., Chaker L., Groeneweg S., Li Y., Di Munno C., Barbieri C. et al. Genome-wide analyses identify a role for SLC17A4 and AADAT in thyroid hormone regulation. Nat. Commun. 2018;9(1):4455. DOI: 10.1038/s41467-018-06356-1.
Garber J.R., Cobin R.H., Gharib H., Hennessey J.V., Klein I., Mechanick J.I. et al. Clinical practice guidelines for hypothyroidism in adults: co-sponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Endocr. Pract. 2012;18(6):988-1028. DOI: 10.4158/EP12280.GL.
Huang S.A., Fish S.A., Dorfman D.M., Salvatore D., Kozakewich H.P., Mandel S.J. et al. A 21-year-old woman with consumptive hypothyroidism due to a vascular tumor expressing type 3 iodothyronine deiodinase. J. Clin. Endocrinol. Metab. 2002;87(10):4457-4461. DOI: 10.1210/jc.2002-020627.
Mouat F., Evans H.M., Cutfield W.S., Hofman P.L., Jefferies C. Massive hepatic hemangioendothelioma and consumptive hypothyroidism. J. Pediatr. Endocrinol. Metab. 2008;21(7):701-703. DOI: 10.1515/ jpem.2008.21.7.701.
Jonklaas J., Bianco A.C., Bauer A.J., Burman K.D., Cappola A.R., Celi F.S. et al. Guidelines for the treatment of hypothyroidism: Prepared by the american thyroid association task force on thyroid hormone replacement. Thyroid. 2014;24(12):1670-1751. DOI: 10.1089/ thy.2014.0028.
Ettleson M.D., Bianco A.C. Individualized therapy for Hypothyroidism: Is T4 enough for everyone? J. Clin. Endocrinol. Metab. 2020;105(9):e3090-e3104. DOI: 10.1210/clinem/dgaa430.
McAninch E.A., Bianco A.C. The history and future of treatment of hypothyroidism. Ann. Intern. Med. 2016;164(1):50-56. DOI: 10.7326/M15-1799.
Grover G.J., Mellstrom K., Malm J. Therapeutic potential for thyroid hormone receptor-beta selective agonists for treating obesity, hyperlip-idemia and diabetes. Curr. Vasc. Pharmacol. 2007;5(2):141-154. DOI: 10.2174/157016107780368271.
Brent G.A. Mechanisms of thyroid hormone action. J. Clin. Invest. 2012;122(9):3035-3043. DOI: 10.1172/JCI60047.
Mendoza A., Hollenberg A.N. New insights into thyroid hormone action. Pharmacol. Ther. 2017;173:135-145. DOI: 10.1016/j. pharmthera.2017.02.012.
Saponaro F., Sestito S., Runfola M., Rapposelli S., Chiellini G. Selective thyroid hormone receptor-beta (TRp) agonists: New perspectives for the treatment of metabolic and neurodegenerative disorders. Front. Med. (Lausanne). 2020;7:331. DOI: 10.3389/fmed.2020.00331.
Meruvu S., Ayers S.D., Winnier G., Webb P. Thyroid hormone analogues: where do we stand in 2013? Thyroid. 2013;23(11):1333-1344. DOI: 10.1089/thy.2012.0458.
Jeong S.W. Nonalcoholic fatty liver disease: A drug revolution is coming. Diabetes Metab. J. 2020;44(5):640-657. DOI: 10.4093/ dmj.2020.0115.
Bakhtyukov A.A., Derkach K.V., Fokina E.A., Sorokoumov V.N., Zakharova I.O., Bayunova L.V. et al. Development of low-molecular-weight allosteric agonist of thyroid-stimulating hormone receptor with thyroidogenic activity. Dokl. Biochem. Biophys. 2022;503(1):67-70. DOI: 10.1134/S1607672922020016.
Shpakov A.O., Shpakova E.A., Derkach K.V. The sensitivity of the adenylyl cyclase system in rat thyroidal and extrathyroidal tissues to peptides corresponding to the third intracellular loop of thyroid-stimulating hormone receptor. Current Topics in Peptide & Protein Research. 2012;13:61-73.
Derkach K.V., Shpakova E.A., Titov A.K. et al. Intranasal and intramuscular administration of lysine-palmitoylated peptide 612-627 of thyroid-stimulating hormone receptor increases the level of thyroid hormones in rats. Int. J. Pept. Res. Ther. 2015;21:249-260. DOI: 10.1007/ s10989-014-9452-6.

Еще

Статья научная